United Kingdom

Oncology

We work hard to ease the way for people with cancer throughout their treatment journey and to offer choice and scientific based information to oncology specialists.


We focus on supporting the NHS in managing conditions like cancer. Our aim is to work in partnership to develop joined-up care through Joint Working projects, to improve patient outcomes and enhance patient experience, and also to offer value for money. That might be through medicines optimisation, quality improvement, pathway redesign or improvement, innovation or identifying cost efficiencies.

Our medicines treat cancer and associated conditions like chemotherapy-induced neutropenia and breakthrough cancer pain.

Cancer is a major cause of morbidity and mortality throughout the world. In the UK, every two minutes someone is diagnosed with cancer.1

In our portfolio of generic medicines, we have treatments for a wide range of cancer types. Our Specialty lines focus on chemotherapy-induced neutropenia, acute promyelocytic leukaemia and metastatic breast cancer.

Lonquex® (lipegfilgrastim)

Lonquex® is indicated for the reduction of the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).2

Trisenox® (arsenic trioxide)

Trisenox® is indicated for induction of remission and consolidation in adult patients with relapsed/refractory acute promyelocytic leukaemia (APL), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene. Previous treatment should have included a retinoid and chemotherapy.3

Myocet® (liposomal doxorubicin)

Myocet®, in combination with cyclophosphamide, is indicated for the first line treatment of metastatic breast cancer in adult women.4


Support for healthcare professionals
__________________________________________________________________________________________________________________

  • For factual, scientific-based information about Lonquex®, Trisenox® and Myocet® contact Teva’Medical Information Service via e-mail medinfo@tevauk.com or call0207 540 7117
  • Further information, including Prescribing Information for Lonquex®, Trisenox®and Myocet® is available from the respective pages linked to above
  • You can also request a visit from a Teva representative here

Joint Working
__________________________________________________________________________________________________________________

Our Joint Working projects help the NHS and healthcare professionals deliver improved patient outcomes. Our Joint Working projects are available on our Joint Working pages.

To discuss potential Joint Working opportunities with Teva within oncology you can contact us and a representative from Teva will be in touch.

___________________________________________________________________________________________________

References:

[1] http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence#heading-Zero [accessed 31/03/16].

[2] Lonquex® (lipegfilgrastim) Summary of Product Characteristics.

[3] Trisenox® (arsenic trioxide) Summary of Product Characterisitics.

[4] Myocet® (doxorubicin) Summary of Product Characterisitics.

Teva Ref: HC609